KPKaren Peynshaert

Karen Peynshaert

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Karen Peynshaert has a total of 100 co-authors. Here are the top co-authors by number of shared publications:

  • Katrien Remaut

    Laboratory of General Biochemistry and Physical Pharmacy, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium

    13 shared publications
  • Stefaan C. De Smedt

    Laboratory of General Biochemistry and Physical Pharmacy, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium

    12 shared publications
  • Joke Devoldere

    Lab of General Biochemistry and Physical Pharmacy, Faculty of Pharmaceutical Sciences, Ghent University, Belgium Belgium

    8 shared publications
  • Katrien Remaut

    Laboratory of General Biochemistry and Physical Pharmacy, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium

    8 shared publications
  • Kevin Braeckmans

    Laboratory of General Biochemistry and Physical Pharmacy, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium

    8 shared publications
  • Stefaan C. De Smedt

    Ghent Research Group on Nanomedicines, Laboratory of General Biochemistry and Physical Pharmacy, Faculty of Pharmaceutical Sciences, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium

    6 shared publications

Latest Publications

  • Open Access

    Photodisruption of the Inner Limiting Membrane Promotes Retinal Engraftment of Stem-Cell Derived Retinal Ganglion Cells

    by Emma De Coster, Kaat De Clerck, Chloë De Clercq, Weiran Li, Deep Punj, Bernd Vanmeerhaeghe, Jonie Verdonck, Stefaan De Smedt, Kevin Braeckmans, Hanieh Hadady, et al.

    The purpose of this study is to address the challenge of limited donor retinal ganglion cell (RGC) migration into the retina after transplantation, which is largely due to donor neuron accumulation at the inner limiting membrane (ILM). We present a minimally invasive technique, ILM photodisruption, to locally ablate the ILM and thereby promote RGC engraftment. ILM photodisruption uses indocyanine green as a photosensitizer, which is delivered to the ILM and activated with ultra-short laser pulses. This process generates vapor nanobubbles (VNBs) that, upon collapse, create localized disruptions in the ILM. In this study, we finetuned this technology in bovine and postmortem human organotypic retinal explants to generate patterned ILM pores. To assess the impact of these photodisruption patterns on RGC transplantation, we applied induced pluripotent stem cell (iPSC)-derived RGCs to the ILM surface and co-cultured them for 7 days. Using advanced microscopy and spatial metric tools, we assessed donor RGC survival, spreading, and neurite localization. We compared ILM photodisruption to a current standard method of enzymatically digesting the ILM. ILM photodisruption was highly effective in creating pores in both the bovine ILM and the thicker, more complex human ILM. In contrast, collagenase treatment had no effect on the human ILM. Both collagenase and ILM photodisruption significantly promoted donor RGC survival, enhanced cell spreading, and resulted in more neurites that extended deeper into the retina. Our findings demonstrate that ILM photodisruption can overcome a key barrier in RGC replacement therapy and, as such, may help advance vision restoration strategies for glaucoma.


  • Strategic lipid nanoparticle design dictates retinal delivery post inner limiting membrane disruption

    by Kaat De Clerck, Emma De Coster, Luca Paoletti, Stefaan De Smedt, Katrien Remaut, Karen Peynshaert

    The interest in lipid nanoparticle (LNP)-mediated mRNA delivery significantly accelerated in the aftermath of the clinical success of mRNA-based COVID-19 vaccines. Validated as an effective and scalable platform, LNPs are now considered a cornerstone technology for the development of next-generation nucleic acid therapeutics. Recently, mRNA therapy entered the field of retinal gene therapy where it could treat retinal disorders contributing to the global numbers of vision impairment and blindness. While an historically driven focus on targeting outer retinal cells was initially in place, a shift toward delivery to the inner retina via intravitreal injection is ongoing. Yet, successful delivery is cumbersome since many nanocarriers are trapped at the inner limiting membrane (ILM). Therefore, this study enlightens the role of the ILM barrier with due consideration how fine-tuning LNP design impacts delivery after ILM disruption. For a standard LNP composition, we showed that ILM disruption is resulting in remarkable amounts of mRNA expression as opposed to an intact ILM. Based on an in-depth in vitro screening, the standard DSPC helper lipid was switched to DOPE to enhance expression levels and the percentage of PEGylation was adjusted to define LNP size. Despite the negative impact of elevated PEGylation on transfection efficiency in vitro, a significant boost in transfected retinal cells was noticed in an ex vivo setting due to improved penetration in the retina. In conclusion, we demonstrated that strategic design of LNP composition can boost LNP delivery beyond the ILM barrier and drive mRNA-LNP therapy to the retina forward. Graphical abstract


  • Advancing nanoparticle delivery studies: flow cytometry-based quantification of nanoparticle uptake and transfection in retinal tissue

    by Luca Paoletti, Kaat De Clerck, Emma De Coster, Pietro Matricardi, Katrien Remaut, Karen Peynshaert

    Millions of people worldwide suffer from vision impairments, significantly affecting their quality of life and mental health and imposing a massive economic burden on healthcare. The eye, converting light into signals for the brain, plays a key role in vision, with the retina being especially vital yet susceptible to damage. Gene therapy holds promise for effectively treating vision-related diseases. However, in basic research, screening for effective gene carriers often lacks quantitative evaluation. One major challenge in translating promising nanoparticles from in vitro studies to (pre)clinical applications is the presence of retinal drug delivery barriers. Ex vivo experimentation could help overcome that by providing insights into these barriers early on, yet much of the current research relies heavily on qualitative assessments. Specifically, the lack of quantitative methods to assess nanoparticle penetration in the retina moved us to develop a flow cytometry-based method for large animal retinal tissue. Our method proved to efficiently quantify both nanoparticle uptake and transfection in the retina, corroborating our qualitative outcomes and positioning itself as a useful tool to support the drug and gene delivery community. Graphical Abstract


  • Open Access

    Photodisruption of the inner limiting membrane promotes retinal engraftment of stem-cell derived retinal ganglion cells

    by E. De Coster, K. De Clerck, C. De Clercq, W. Li, D. Punj, B. Vanmeerhaeghe, S. De Smedt, K. Braeckmans, H. Hadady, K. Remaut, et al.

    Glaucoma is the leading cause of irreversible blindness, driven by the progressive loss of retinal ganglion cells (RGCs). Stem cell-derived RGC transplantation could revolutionize glaucoma treatment, but the inner limiting membrane (ILM) remains a major obstacle by hindering cell migration into the retina. Interestingly, the ILM represents a double-edged sword for RGC engraftment: on the one hand, it greatly hinders cell migration, whereas on the other hand, its presence during retinal development is necessary for neuronal migration and retinal lamination. As an alternative to current invasive and harmful strategies to disrupt the ILM, we introduce ILM photodisruption, a minimally invasive biophotonic method that can manipulate the integrity of the ILM with unprecedented precision. In this study, we have finetuned the technology in bovine and human organotypic retinal explants to create templated ILM pores, creating entryways for donor RGCs to enter the retina while preserving most of the membrane to confer guidance cues for their engraftment. Applying this technology, we were able to promote donor RGC survival, enhance cell spreading and facilitate integration into the retina. Overall, our findings demonstrate that ILM photodisruption effectively addresses a key barrier in RGC replacement, paving the way for advancing retinal regeneration toward clinical application.


  • Less is more: Self-amplifying mRNA becomes self-killing upon dose escalation in immune-competent retinal cells

    by Helena Vanluchene, Oriane Gillon, Karen Peynshaert, Stefaan C. De Smedt, Niek Sanders, Koen Raemdonck, Katrien Remaut


  • Every nano-step counts: a critical reflection on do’s and don’ts in researching nanomedicines for retinal gene therapy

    by Karen Peynshaert, Joke Devoldere, Stefaan De Smedt, Katrien Remaut

    Retinal disease affects millions of people worldwide, generating a massive social and economic burden. Current clinical trials for retinal diseases are dominated by gene augmentation therapies deli...


  • Open Access

    Photodisruption of the Inner Limiting Membrane: Exploring ICG Loaded Nanoparticles as Photosensitizers

    by Kaat De Clerck, Geraldine Accou, Félix Sauvage, Kevin Braeckmans, Stefaan C. De Smedt, Katrien Remaut, Karen Peynshaert

    The inner limiting membrane (ILM) represents a major bottleneck hampering efficient drug delivery to the retina after intravitreal injection. To overcome this barrier, we intend to perforate the ILM by use of a light-based approach which relies on the creation of vapor nanobubbles (VNBs) when irradiating photosensitizers with high intensity laser pulses. Upon collapse of these VNBs, mechanical effects can disrupt biological structures. As a photosensitizer, we explore indocyanine green (ICG) loaded nanoparticles (NPs) specifically designed for our application. In light of this, ICG liposomes and PLGA ICG NPs were characterized in terms of physicochemical properties, ICG incorporation and VNB formation. ICG liposomes were found to encapsulate significantly higher amounts of ICG compared to PLGA ICG NPs which is reflected in their VNB creating capacity. Since only ICG liposomes were able to induce VNB generation, this class of NPs was further investigated on retinal explants. Here, application of ICG liposomes followed by laser treatment resulted in subtle disruption effects at the ILM where zones of fully ablated ILM were alternated by intact regions. As the interaction between the ICG liposomes and ILM might be insufficient, active targeting strategies or other NP designs might improve the concept to a further extent.


  • Laser-induced nanobubbles safely ablate vitreous opacities in vivo

    by Félix Sauvage, Van Phuc Nguyen, Yanxiu Li, Aranit Harizaj, J. Sebag, Dimitri Roels, Viktor Van Havere, Karen Peynshaert, Ranhua Xiong, Juan C. Fraire, et al.

    In myopia, diabetes and ageing, fibrous vitreous liquefaction and degeneration is associated with the formation of opacities inside the vitreous body that cast shadows on the retina, appearing as ‘floaters’ to the patient. Vitreous opacities degrade contrast sensitivity function and can cause notable impairment in vision-related quality of life. Here we introduce ‘nanobubble ablation’ for safe destruction of vitreous opacities. Following intravitreal injection, hyaluronic acid-coated gold nanoparticles and indocyanine green, which is widely used as a dye in vitreoretinal surgery, spontaneously accumulate on collagenous vitreous opacities in the eyes of rabbits. Applying nanosecond laser pulses generates vapour nanobubbles that mechanically destroy the opacities in rabbit eyes and in patient specimens. Nanobubble ablation might offer a safe and efficient treatment to millions of patients suffering from debilitating vitreous opacities and paves the way for a highly safe use of pulsed lasers in the posterior segment of the eye.


  • Open Access

    Vaccinia Virus Protein B18R: Influence on mRNA Immunogenicity and Translation upon Non-Viral Delivery in Different Ocular Cell Types

    by An-Katrien Minnaert, Joke Devoldere, Karen Peynshaert, Laure Vercruysse, Stefaan C. De Smedt, Katrien Remaut

    In the last few years, interest has grown in the use of nucleic acids as an ocular therapy for retinal genetic diseases. Recently, our research group has demonstrated that mRNA delivery could result in effective protein expression in ocular cells following subretinal injection. Yet, although mRNA therapy comes with many advantages, its immunogenicity resulting in hampered mRNA translation delays development to the clinic. Therefore, several research groups investigate possible strategies to reduce this innate immunity. In this study, we focus on B18R, an immune inhibitor to suppress the mRNA-induced innate immune responses in two ocular cell types. We made use of retinal pigment epithelial (RPE) cells and Müller cells both as immortalized cell lines and primary bovine cells. When cells were co-incubated with both B18R and mRNA-MessengerMAX lipoplexes we observed an increase in transfection efficiency accompanied by a decrease in interferon-β production, except for the Müller cells. Moreover, uptake efficiency and cell viability were not hampered. Taken together, we showed that the effect of B18R is cell type-dependent but remains a possible strategy to improve mRNA translation in RPE cells.